Samsung Biologics

28/05/2026

Samsung Biologics is broadening its global manufacturing reach through the Rockville Campus in the U.S. 🌏

As part of our ongoing efforts to enhance client proximity and manufacturing diversification, the Rockville Campus strengthens flexibility and regional connectivity across our global network.

Together, the campuses in Songdo and Rockville will help reinforce supply resilience and support seamless collaboration for partners worldwide.

Biologics

20/05/2026

As the biopharmaceutical industry moves toward greater complexity and digitalization, the role of Manufacturing Science and Technology (MSAT) is becoming increasingly central to operational excellence.

🎥 In this episode of Leaders in Focus, Bram ten Cate, Vice President of MSAT at Samsung Biologics, explains how deep process understanding (underpinned by PAT and QbD principles), standardized workflows, and seamless digital integration can accelerate technology transfer and boost the reproducibility of manufacturing outcomes.

“MSAT will evolve from being a support function to a strategic enabler—connecting data, science, and ex*****on to deliver reliability at scale.”

💡 The accompanying newsroom article delves further into the expanding role of MSAT and the integration of digital tools across biomanufacturing. https://samsungbiologics.com/media/bio-story/leaders-in-focus-turning-complexity-into-predictable-ex*****on

13/05/2026

삼성바이오로직스, 美 '2026 PEGS 보스턴' 참가
https://samsungbiologics.com/kr/media/company-news/samsung-biologics-participates-in-the-us-2026-pegs-boston

삼성바이오로직스(대표이사 존 림)는 글로벌 바이오의약품 기술 학회인 '단백질·항체 공학 서밋(PEGS) 보스턴'에 참가해 글로벌 고객과의 접점 확대에 나섰다고 13일(수) 밝혔다. 특히 항암신약 개발의 효율성과 성공 가능.....

08/05/2026

🌟 Meet Kateryna Mykhailova, Scientist, MSAT Upstream at Samsung Biologics.

Kateryna plays a critical role in advancing efficient tech transfer and upstream process optimization by developing predictive, small-scale models that closely replicate large-scale manufacturing conditions.

These advanced scale-down models enable early identification of potential process risks, helping reduce variability and ensure consistent performance from development through commercial manufacturing.

As biomanufacturing continues to evolve toward a more data-driven paradigm, this level of process insight is becoming essential to achieving faster, more reliable tech transfer outcomes.

Watch the video below to learn how Kateryna is contributing to a more predictive and robust future in upstream development.

DataDriven Innovation

06/05/2026

삼성 라이프사이언스펀드, 美 바이오텍 '카토그래피 바이오사이언스' 투자

https://samsungbiologics.com/kr/media/company-news/samsung-life-science-fund-invests-in-cartography-biosciences

삼성 라이프사이언스 펀드(Samsung Life Science Fund)가 미국 바이오 벤처 기업인 카토그래피 바이오사이언스(Cartography Biosciences)에 투자한다고 밝혔다.

05/05/2026

삼성바이오로직스, 다우존스 베스트인클래스 월드 지수 5년 연속 편입

👀👉https://samsungbiologics.com/kr/media/company-news/samsung-biologics-listed-on-dow-jones-best-in-class-world-index-for-fifth-consecutive-year

삼성바이오로직스(대표이사 존 림)가 글로벌 ESG 평가 지표인 다우존스 베스트인클래스 월드 지수(Dow Jones Best-in-Class World Index)에 5년 연속 편입됐다고 28일(화) 밝혔다.

22/04/2026

삼성바이오로직스, 1분기 매출 1조2571억원·영업이익 5808억원 기록

👀👉https://samsungbiologics.com/kr/media/company-news/samsung-biologics-reports-first-quarter-2026-financial-results

삼성바이오로직스(대표이사 존 림)가 22일(수) 공시를 통해 1분기 매출 1조2571억원, 영업이익 5808억원을 기록했다고 밝혔다. 이는 1~4공장의 풀가동에 힘입은 성과로, 전년 동기 대비 매출은 2576억원(+26%), 영업이익은 1506억원(+35%) ....

19/04/2026

삼성바이오로직스, 글로벌 최대 암 학회에서 'CRDMO' 사업 경쟁력 알린다

👀👉https://samsungbiologics.com/kr/media/company-news/samsung-biologics-crdmo-strengths-at-aacr-annual-meeting-2026

#삼성바이오로직스

- '세계 3대 암 학회' AACR에서 CRO·CDO 기술력 적극 알려- 현장 발표 통해 '삼성 오가노이드'·'에스-듀얼(S-DUAL)®' 등 홍보- 후보물질 발굴부터 상업화까지 전 주기 CRDMO 역량으로 고객 수요 대응삼성바이오로직스(대표이사: 존 림)는 ...

10/04/2026

Hello, Rockville. 👋

Samsung Biologics has diversified its manufacturing network with the addition of our Rockville campus. 🌏📍🇺🇸

With our U.S. facility, we are further strengthening our ability to deliver with greater proximity, capacity, and supply continuity.

Connect with our experts to explore how we can support your programs.

01/04/2026

삼성바이오로직스, 美 록빌 바이오의약품 생산시설 인수 완료🇰🇷🇺🇸🎉

👀👉https://samsungbiologics.com/kr/media/company-news/samsung-biologics-completes-acquisition-of-gsks-manufacturing-facility-in-rockville-maryland

미국 메릴랜드주 록빌 바이오의약품 생산시설에서 열린 인수 완료식에서 참석자들이 기념 촬영을 하고 있다. 사진 앞줄 다섯번째부터 강경화 주미한국대사, 존림 삼성바이오로직스 대표, 웨스 무어 메릴랜드 주지사, 에이프릴 ...

31/03/2026

Samsung Biologics completes acquisition of GSK’s manufacturing facility in Rockville, Maryland

👀👉https://samsungbiologics.com/media/company-news/samsung-biologics-completes-acquisition-of-gsks-manufacturing-facility-in-rockville-maryland

Incheon, S. Korea and Maryland, United States, March 31, 2026 – Samsung Biologics (KRX: 207940.KS), a leading contract development and manufacturing organization (CDMO), today announced the completion of its acquisition of a manufacturing facility in Rockville, Maryland from GSK, establishing the ...